Briggs Morrison - 05 Jun 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: Director
Issuer ticker: CRSP
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 17:30:30 UTC
Prior SEC filing: 27 Jun 2024
Next SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Ryland Waldinger

Key filing fact

Briggs Morrison filed Form 4 for CRISPR Therapeutics AG (CRSP) on 06 Jun 2025.

Key facts

This page summarizes Briggs Morrison's Form 4 filing for CRISPR Therapeutics AG (CRSP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 17:30.

Change

Previous filing in this sequence was filed on 27 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001654430 Primary reporting owner

Morrison Briggs

Relationship: Director
Address: C/O CRIPSR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: /s/ Elizabeth Ryland Waldinger
Signature date: 06 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +13,000
Change %
Price: $0.000000
Shares after: 13,000
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 13,000
Exercise price: $38.57
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders.